Donnenfeld Eric D, Perry Henry D, Nattis Alanna S, Rosenberg Eric D
a Ophthalmic Consultants of Long Island, New York University Medical Center , Garden City , NY , USA.
b Ophthalmic Consultants of Long Island, Nassau University Medical Center , Rockville Centre , NY , USA.
Expert Opin Pharmacother. 2017 Oct;18(14):1517-1524. doi: 10.1080/14656566.2017.1372748. Epub 2017 Sep 4.
Dry eye disease (DED) is a common ocular disorder that can have a substantial burden on quality of life and daily activities. Lifitegrast ophthalmic solution 5.0% is the first medication approved in the US for the treatment of the signs and symptoms of DED. The aim of this article is to summarize the preclinical and clinical data on lifitegrast and discuss how lifitegrast may fit into the current treatment landscape for DED. Areas covered: A literature search of published preclinical and clinical data was conducted to review the chemistry, pharmacodynamics, pharmacokinetics, and clinical efficacy/safety of lifitegrast. The impact that lifitegrast may have on DED treatment practices is also discussed. Expert opinion: The introduction of lifitegrast provides a potentially important additional option for eye care professionals treating DED. In clinical trials conducted in adults with DED, lifitegrast ophthalmic solution 5.0% improved both signs and symptoms of DED. Of note, in 2 phase 3 trials, symptom improvements were observed as early as 2 weeks, which may be explained by lifitegrast's unique mechanism of action of blocking a specific signaling pathway in inflammation. Future research should include evaluation of whether lifitegrast can be used in combination with other DED treatments.
干眼症（DED）是一种常见的眼部疾病，会对生活质量和日常活动造成相当大的负担。5.0%的lifitegrast眼药水是美国首个获批用于治疗干眼症体征和症状的药物。本文旨在总结关于lifitegrast的临床前和临床数据，并讨论lifitegrast如何适用于当前干眼症的治疗格局。涵盖领域：对已发表的临床前和临床数据进行文献检索，以回顾lifitegrast的化学性质、药效学、药代动力学以及临床疗效/安全性。还讨论了lifitegrast可能对干眼症治疗实践产生的影响。专家意见：lifitegrast的推出为治疗干眼症的眼科护理专业人员提供了一个潜在的重要额外选择。在针对成年干眼症患者进行的临床试验中，5.0%的lifitegrast眼药水改善了干眼症的体征和症状。值得注意的是，在两项3期试验中，早在2周时就观察到了症状改善，这可能是由于lifitegrast阻断炎症中特定信号通路的独特作用机制所致。未来的研究应包括评估lifitegrast是否可与其他干眼症治疗方法联合使用。
